IL4 and IFNalpha generation of dendritic cells reveals great migratory potential and NFkB and cJun expression in IL4DCs

References

• Banchereau J, Steinman RM. (1998). Dendritic cells and the control of immunity. Nature, 392, 245–52
   PubMed Web of Science ®Google Scholar
• Belardelli F, Ferrantini M, Proietti E, Kirkwood JM. (2002). Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev, 13, 119–34
   PubMed Web of Science ®Google Scholar
• Chan SH, Perussia B, Gupta JW, et al. (1991). Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med, 173, 869–79
   PubMed Web of Science ®Google Scholar
• Cranmer LD, Trevor KT, Hersh EM. (2004). Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol Immunother, 53, 275–306
   PubMed Web of Science ®Google Scholar
• Detournay O, Mazouz N, Goldman M, Toungouz M. (2005). IL-6 produced by type I IFN DC controls IFN-gamma production by regulating the suppressive effect of CD4+ CD25+ regulatory T cells. Hum Immunol, 66, 460–8
   PubMed Web of Science ®Google Scholar
• Dieu MC, Vanbervliet B, Vicari A, et al. (1998). Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med, 188, 373–86
   PubMed Web of Science ®Google Scholar
• Gately MK, Desai BB, Wolitzky AG, et al. (1991). Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol, 147, 874–82
   PubMed Web of Science ®Google Scholar
• Gately MK, Warrier RR, Honasoge S, et al. (1994). Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-gamma in vivo. Int Immunol, 6, 157–67
   PubMed Web of Science ®Google Scholar
• Gillessen S, Carvajal D, Ling P, et al. (1995). Mouse interleukin-12 (IL-12) p40 homodimer: a potent IL-12 antagonist. Eur J Immunol, 25, 200–6
   PubMed Web of Science ®Google Scholar
• Hsieh CS, Macatonia SE, Tripp CS, et al. (1993). Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science, 260, 547–9
   PubMed Web of Science ®Google Scholar
• Jonuleit H, Kuhn U, Muller G, et al. (1997). Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol, 27, 3135–42
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Tramsen L, Koehl U, et al. (2013). Immunotherapy against invasive fungal diseases in stem cell transplant recipients. Immunol Invest, 40, 839–52
   Web of Science ®Google Scholar
• Luft T, Pang KC, Thomas E, et al. (1998). Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol, 161, 1947–53
   PubMed Web of Science ®Google Scholar
• Ma W, Gee K, Lim W, et al. (2004). Dexamethasone inhibits IL-12p40 production in lipopolysaccharide-stimulated human monocytic cells by down-regulating the activity of c-Jun N-terminal kinase, the activation protein-1, and NF-kappa B transcription factors. J Immunol, 172, 318–30
   PubMed Web of Science ®Google Scholar
• Manetti R, Parronchi P, Giudizi MG, et al. (1993). Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med, 177, 1199–204
   PubMed Web of Science ®Google Scholar
• Mocellin S, Mandruzzato S, Bronte V, et al. (2004). Part I: Vaccines for solid tumours. Lancet Oncol, 5, 681–9
   PubMed Web of Science ®Google Scholar
• Mule JJ. (2000). Dendritic cells: at the clinical crossroads. J Clin Invest, 105, 707–8
   PubMed Web of Science ®Google Scholar
• Munz C, Steinman RM, Fujii S. (2005). Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J Exp Med, 202, 203–7
   PubMed Web of Science ®Google Scholar
• Nestle FO, Farkas A, Conrad C. (2005). Dendritic-cell-based therapeutic vaccination against cancer. Curr Opin Immunol, 17, 163–9
   PubMed Web of Science ®Google Scholar
• Oppmann B, Lesley R, Blom B, et al. (2000). Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity, 13, 715–25
   PubMed Web of Science ®Google Scholar
• Qian C, Jiang X, An H, et al. (2006). TLR agonists promote ERK-mediated preferential IL-10 production of regulatory dendritic cells (diffDCs), leading to NK-cell activation. Blood, 108, 2307–15
   PubMed Web of Science ®Google Scholar
• Sallusto F, Cella M, Danieli C, Lanzavecchia A. (1995). Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med, 182, 389–400
   PubMed Web of Science ®Google Scholar
• Sallusto F, Schaerli P, Loetscher P, et al. (1998). Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur J Immunol, 28, 2760–9
   PubMed Web of Science ®Google Scholar
• Sallusto F, Palermo B, Lenig D, et al. (1999). Distinct patterns and kinetics of chemokine production regulate dendritic cell function. Eur J Immunol, 29, 1617–25
   PubMed Web of Science ®Google Scholar
• Santini SM, Lapenta C, Logozzi M, et al. (2000). Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med, 191, 1777–88
   PubMed Web of Science ®Google Scholar
• Son CH, Bae JH, Shin DY, et al. (2013). Enhanced Maturation and Function of Dendritic Cells Using Hydrogel Coated Plate and Antigen Electroporation. Immunol Invest, 42, 341–55
   PubMed Web of Science ®Google Scholar
• Sozzani S, Allavena P, D'Amico G, et al. (1998). Differential regulation of chemokine receptors during dendritic cell maturation: a model for their trafficking properties. J Immunol, 161, 1083–6
   PubMed Web of Science ®Google Scholar
• Taganov KD, Boldin MP, Chang KJ, Baltimore D. (2006). NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A, 103, 12481–6
   PubMed Web of Science ®Google Scholar
• Tatsumi T, Kierstead LS, Ranieri E, et al. (2002). Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med, 196, 619–28
   PubMed Web of Science ®Google Scholar